Drug Profile
Carbidopa/levodopa - Cellix Bio
Alternative Names: CLX-107; CLX-CNX-07Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Cellix Bio
- Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Parkinson's-disease in India
- 18 Jan 2019 Chemical structure information added
- 20 Feb 2018 Cellixbio has patent protection for compositions and methods for the treatment of Parkinson’s disease in USA, before February 2018 (Cellixbio pipeline, February 2018)